Document is current
Any future updates will be listed below
-
Authors
Calafate, Sara https://orcid.org/0000-0002-1276-3211
Özturan, Gökhan
Thrupp, Nicola
Vanderlinden, Jeroen
Santa-Marinha, Luísa
Morais-Ribeiro, Rafaela
Ruggiero, Antonella
Bozic, Ivan
Rusterholz, Thomas
Lorente-Echeverría, Blanca
Dias, Marcelo https://orcid.org/0000-0003-1844-8631
Chen, Wei-Ting
Fiers, Mark
Lu, Ashley
Vlaeminck, Ine https://orcid.org/0000-0001-8934-6179
Creemers, Eline
Craessaerts, Katleen
Vandenbempt, Joris
van Boekholdt, Luuk https://orcid.org/0000-0001-5809-8379
Poovathingal, Suresh
Davie, Kristofer https://orcid.org/0000-0003-2182-1249
Thal, Dietmar Rudolf https://orcid.org/0000-0002-1036-1075
Wierda, Keimpe
Oliveira, Tiago Gil https://orcid.org/0000-0003-0509-0562
Slutsky, Inna https://orcid.org/0000-0002-0700-2266
Adamantidis, Antoine https://orcid.org/0000-0003-2531-5175
De Strooper, Bart https://orcid.org/0000-0001-5455-5819
de Wit, Joris https://orcid.org/0000-0003-1120-1089
- License Information
-
More Information
Article History
Received: 6 October 2022
Accepted: 10 April 2023
First Online: 15 May 2023
Competing interests
: D.R.T. received speaker honorarium from Biogen (USA), travel reimbursement from UCB (Belgium) and collaborated with GE HealthCare (United Kingdom), Novartis Pharma Basel (Switzerland), Probiodrug (Germany) and Janssen Pharmaceutical Companies (Belgium). T.G.O. is a scientific advisor board member and shareholder of Ceracuity (USA) and collaborated with Biogen (USA). B.D.S. is or has been consultant for Eisai, AbbVie, K5/Muna; co-founder of Augustine Tx; and founder and shareholder of K5/Muna. J.d.W. is co-founder and scientific advisory board member of Augustine Tx. All other authors declare no competing interests.
